Lymphoma SIG Podcast 13 – BSH 2025 Highlights – Top Abstracts in Lymphoma with Dr Cathy Burton

Lymphoma Sig Podcast Episode 14 Mantle cell lymphoma – first-line treatment in 2025 – by Dr David Lewis

This podcast is the first of a series of three recordings of the Lymphoma Special Interest Group (SIG) Education Session at the 2025 BSH Annual Scientific Meeting.  The Lymphoma SIG is delighted to share talks from three great speakers with the wider audience.   In this recording, Dr David Lewis discusses first-line treatment for mantle cell lymphoma in 2025, focusing on three main themes: 1) the emerging use of Bruton’s tyrosine kinase inhibitors (BTKis) in first-line treatment, 2) the role of autologous stem cell transplant, and 3) the clinical utility of minimal residual disease (MRD).   Dr David Lewis is a Consultant Haematologist at the University Hospitals Plymouth and an Honorary Associate Professor at the University of Plymouth.  He is the Chief Investigator of the ENRICH trial – a randomised, open-label study of Rituximab/Ibrutinib versus. Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma.

Lymphoma SIG Podcast 13 – BSH 2025 Highlights – Top Abstracts in Lymphoma with Dr Cathy Burton

Dr Cathy Burton chaired the “Top Abstracts in Lymphoma” session at BSH 2025.  In this episode, she shares with us the highlights from this session.   Dr Burton is a Consultant Haematologist at St James’s University Hospital, Leeds, specializing in Lymphoma and Diagnostics. She is heavily engaged in translational research in lymphoma and is Chair of the Hodgkin lymphoma study group, Deputy Chair of the Lymphoma Science study group and a member of the UK Lymphoma Research Group. She has recently been involved in writing the diffuse large B cell lymphoma guidelines and is the chair of the BSH Lymphoma Special Interest Group.

Lymphoma SIG Podcast 11 - BSH 2025 Highlights - Dr Sridhar Chaganti updates regarding large B cell lymphoma

In this episode, Dr Sridhar Chaganti shares with us the highlights in large B-cell lymphoma from BSH 2025, including real-world experience in the use of bispecific antibodies and the recent NICE approval of Lisocel as second line treatment.   Dr Chaganti is a Consultant Haemato-oncologist at the University Hospital in Birmingham, with an interest in lymphomas, ALL, stem cell transplantation and immune effector cell therapies including CART cell therapy.  He is the chair of the high-grade lymphoma study group and co-chairs the national CAR-T panel.

Lymphoma SIG Podcast 10 - BSH 2025 Highlights in Hodgkin Lymphoma with Professor Graham Collins

In this episode, Professor Graham Collins shares with us the highlights in Hodgkin lymphoma from BSH 2025.  He takes us through the ECHELON-1 trial, which led to the recent NICE approval of Brentuximab-AVD as a frontline treatment option for advanced stage Hodgkin lymphoma.

Lymphoma SIG Podcast episode 9 - Primary Mediastinal B-Cell Lymphoma

Professor Graham Collins discusses the management of primary mediastinal B-cell lymphoma, from initial treatment considerations to the management of relapsed disease.   Professor Collins is a Consultant Haematologist and the lymphoma lead clinician at the Oxford Cancer and Haematology Centre.  He has particular interests in Hodgkin and high-grade non-Hodgkin lymphoma and he chairs the national CAR-T panel for lymphoma.   Please note that since the recording of this podcast in December 2024, NICE has granted approval for the use of Liso-cel as a second-line treatment option in primary mediastinal B-cell lymphoma.